News >

Combinations Poised to Carry Clinical Benefit in RCC

Caroline Seymour
Published: Thursday, Sep 13, 2018

Bradley A. McGregor, MD

Bradley A. McGregor, MD
Combination therapies have become a standard of care in advanced renal cell carcinoma (RCC) in the United States following the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for patients with intermediate- and poor-risk disease. Bradley McGregor, MD, explained that combination therapies are now poised to have a global impact.

“As we look toward the future of RCC, combination therapy, particularly in the frontline setting, is going to become a new standard of care around the world,” said McGregor, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of Medicine, Harvard Medical School.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication